Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Family Motivational Intervention in Schizophrenia

NCT01167556

Cannabis Schizophrenia

UNKNOWN NA

Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study

NCT07309159

Schizophrenia

NOT_YET_RECRUITING PHASE1/PHASE2

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550

Schizophrenia Dual Diagnosis Schizoaffective Disorder +2 more

COMPLETED PHASE4

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE1/PHASE2

Impact of tDCS on Cannabis Craving in Schizophrenia

NCT05784961

Schizophrenia Cannabis Use Disorder

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse…). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Cannabis Dependence, Continuous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Motivational Therapy

Four motivational interview for cannabis abuse in schizophrenia population during one month

Group Type EXPERIMENTAL

Motivational therapy

Intervention Type BEHAVIORAL

One hour of motivational therapy each weak during 4 weeks

Usual Care

Usual care with intensive psychotherapy

Group Type OTHER

Usual care

Intervention Type BEHAVIORAL

Patients received at least six hour of usual therapy, as in the experimental group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motivational therapy

One hour of motivational therapy each weak during 4 weeks

Intervention Type BEHAVIORAL

Usual care

Patients received at least six hour of usual therapy, as in the experimental group

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Schizophrenia or schizo-affective disorder according to DSM-IV criteria
* Meeting DSM-IV criteria for actual cannabis abuse or dependance
* in current and regular contact with mental health service
* with an age at interview of 18 years or more
* No evidence of organic brain disease or clinically significant concurrent medical illness or learning disability
* Written informed consent was obtained from all subjects (patients and parents).